Patients who have advanced liver disease or other severe symptoms of hepatitis C virus (HCV) infection should be first in line for an expensive new medication for treating HCV, according to a new guideline. The guideline, from the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America, was created with support from the International Antiviral Society–USA (IAS-USA). It is the latest in a series of guidelines from the groups on treating HCV.
Kuehn BM. Guideline: New HCV Drugs Should Go to Sickest Patients. JAMA. 2014;312(11):1084–1085. doi:10.1001/jama.2014.11373
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: